Clinical trial
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent…
NCT00240565 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00240565 |
|---|---|
| Title | Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma |
| Official title | A Single Arm, Open-label, Multicentre, Phase II Study of Tositumomab and Iodine 131-Tositumomab in Subjects With Indolent Non-Hodgkin's Lymphoma Who Have Previously Received Rituximab. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Tositumomab 450 mg, Tositumomab 35 mg |
| Enrollment | 93 |
| Start date | Apr 1, 2004 |
| Primary completion | Feb 1, 2007 |
| Completion | Sep 1, 2011 |
| First posted | Oct 18, 2005 |
| Last update posted | Aug 13, 2012 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: